Finance

Lists
Q1 2027 earnings • in 4 days
See details
STAR:NSE
Strides Pharma Science Ltd
1 016,00 ₹
-1,51%
(-15,60) 1D
24 հլս, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
1 031,60 ₹
High
1 034,40 ₹
Low
1 014,60 ₹
Mkt. cap
93,65 մլրդ
Avg. vol.
165,06 հզր
Volume
80,52 հզր
Dividend
0,49%
Quarterly dividend
1,25 ₹
Ex-dividend date
31 հլս, 2026 թ.
P/E ratio
16,84
52-wk high
1 231,00 ₹
52-wk low
768,65 ₹
EPS
60,34 ₹
Shares outstanding
89,55 մլն
No. of employees
4 հզր
Open
1 031,60 ₹
High
1 034,40 ₹
Low
1 014,60 ₹
Mkt. cap
93,65 մլրդ
Avg. vol.
165,06 հզր
Volume
80,52 հզր
Dividend
0,49%
Quarterly dividend
1,25 ₹
Ex-dividend date
31 հլս, 2026 թ.
P/E ratio
16,84
52-wk high
1 231,00 ₹
52-wk low
768,65 ₹
EPS
60,34 ₹
Shares outstanding
89,55 մլն
No. of employees
4 հզր
News stories
From sources across the web
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3,54 հզր
Founded1990
HeadquartersԲանգալոր, Կառնատակա, Հնդկաստան
Sector-
Websitestrides.com
Next call 4 օրից
հլս 28, երք, 13:00
Fiscal period
Q1 2027
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
- / 13,32 մլրդ
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
11,20 մլրդ
12,21 մլրդ
11,95 մլրդ
13,23 մլրդ
Cost of goods sold
4,44 մլրդ
5,15 մլրդ
4,63 մլրդ
7,19 մլրդ
Cost of revenue
4,44 մլրդ
5,15 մլրդ
4,63 մլրդ
7,19 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,26 մլրդ
2,27 մլրդ
2,30 մլրդ
3,45 մլրդ
Operating expense
5,06 մլրդ
5,24 մլրդ
5,46 մլրդ
4,91 մլրդ
Total operating expenses
9,51 մլրդ
10,39 մլրդ
10,09 մլրդ
12,10 մլրդ
Operating income
1,69 մլրդ
1,82 մլրդ
1,85 մլրդ
1,13 մլրդ
Other non operating income
-388,77 մլն
271,40 մլն
1,07 մլրդ
-1,66 մլրդ
EBT including unusual items
1,22 մլրդ
1,53 մլրդ
2,45 մլրդ
1,48 մլրդ
EBT excluding unusual items
1,30 մլրդ
1,62 մլրդ
2,49 մլրդ
502,07 մլն
Income tax expense
164,50 մլն
215,93 մլն
373,53 մլն
187,70 մլն
Effective tax rate
13,48%
14,10%
15,22%
12,68%
Other operating expenses
2,32 մլրդ
2,47 մլրդ
2,66 մլրդ
928,53 մլն
Net income
996,08 մլն
1,28 մլրդ
2,02 մլրդ
1,27 մլրդ
Net profit margin
8,90%
10,45%
16,92%
9,59%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
404,82 մլն
Interest expense
-
-461,27 մլն
-433,79 մլն
-130,82 մլն
Net interest expenses
-
-461,27 մլն
-433,79 մլն
274,00 մլն
Depreciation and amortization charges
488,86 մլն
496,43 մլն
506,23 մլն
532,49 մլն
EBITDA
2,09 մլրդ
2,31 մլրդ
2,25 մլրդ
1,55 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer